论文部分内容阅读
目的探讨18F-FDG符合线路SPECT/CT检查诊断卵巢肿瘤治疗后复发及转移的价值。方法对40例临床疑有复发和转移的卵巢癌患者行18F-FDG符合线路SPECT/CT显像,并将结果与病理检查结果比较。结果病理检查证实36例均复发或转移。18F-FDG符合线路SPECT/CT显像检查29例阳性,血清CA125示22例升高,与病理检查结果比较,前者监测复发及转移的灵敏度、特异性和准确性分别为80.6%、100.0%、82.5%;后者为61.1%、100.0%、72.5%,二者灵敏度、准确性比较,P均<0.05。结论18F-FDG符合线路SPECT/CT显像监测卵巢癌复发和转移的灵敏度和特异性均优于CA125检测,可提高隐匿性复发或转移病灶的检出率。
Objective To investigate the value of 18F-FDG coincidence SPECT / CT in diagnosis of recurrence and metastasis of ovarian tumors. Methods Forty ovarian cancer patients with suspected clinical recurrence and metastasis underwent 18 F-FDG coincidence SPECT / CT imaging. The results were compared with the pathological findings. Results The pathological examination confirmed that all 36 cases had recurrence or metastasis. The sensitivity, specificity and accuracy of 18F-FDG coincidence SPECT / CT imaging examination in 29 cases and serum CA125 in 22 cases were 80.6% and 100.0%, respectively. Compared with the pathological findings, the sensitivity, specificity and accuracy of the former in detecting recurrence and metastasis were 80.6% 82.5%; the latter was 61.1%, 100.0%, 72.5%, both the sensitivity and accuracy, P <0.05. Conclusion The sensitivity and specificity of 18F-FDG coincidence SPECT / CT imaging in monitoring the recurrence and metastasis of ovarian cancer are better than that of CA125, which can increase the detection rate of occult recurrence or metastasis.